BTK and mantle cell lymphoma: Inhibitors of BTK became a promising therapeutic modality in the treatment of e.g., chronic lymphocytic leukemia (CLL), Waldenstrom macroglobulinemia (WM), and mantle cell lymphoma (MCL) [65,68,69,70].